Perspectives on marijuana use and effectiveness
Open Access
- 1 August 2017
- journal article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 7 (4) , 333-343
Abstract
Background: Interest in and use of marijuana by persons with multiple sclerosis (MS) has increased. While potential benefits have been reported, so have concerns about potential risks. Few large studies have been conducted about the perceptions and current usage of marijuana and medical cannabinoids in persons with MS. Methods: Participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) registry were surveyed in 2014 regarding legality and history of marijuana usage, both before and after diagnosis with MS. Results: A total of 5,481 participants responded, with 78.2% female, 90% relapsing disease at onset, and a current mean age of 55.5 (10.2) years. Sixty-four percent had tried marijuana prior to their MS diagnosis, 47% have considered using for their MS, 26% have used for their MS, 20% have spoken with their physician about use, and 16% are currently using marijuana. Ninety-one percent think marijuana should be legal in some form. Men, those with higher disability, current and past nicotine smokers, and younger age were associated with a higher likelihood of current use. Conclusions: The majority of responders favor legalization and report high interest in the use of marijuana for treatment of MS symptoms, but may be reluctant to discuss this with health care providers. Health care providers should systematically inquire about use of marijuana.Keywords
This publication has 25 references indexed in Scilit:
- Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosisMultiple Sclerosis Journal, 2010
- Validity of performance scales for disability assessment in multiple sclerosisMultiple Sclerosis Journal, 2007
- Medical marijuana and the developing role of the pharmacistAmerican Journal of Health-System Pharmacy, 2007
- Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosisEuropean Journal of Neurology, 2007
- Decreased respiratory symptoms in cannabis users who vaporizeHarm Reduction Journal, 2007
- Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow upJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosisNeurology, 2005
- Patterns of cannabis use among patients with multiple sclerosisNeurology, 2004
- Reliability and validity of two self-report measures of impairment and disability for MSNeurology, 1999
- Rating neurologic impairment in multiple sclerosisNeurology, 1983